Results from this study showed that animals treated with anti-CTLA plus vMyx-hTNF/PBMCs were essentially identical to animals treated with anti-PD-L1 plus vMyx-hTNF/PBMC combination therapy, with 100% of animals in both cohorts surviving out to at least 100 days after tumor inoculation (Figure 5B). The gene discussed is CD274; the disease is neoplasm.